Brian Levy

Company: Inflammx Therapeutics

Job title: Chief Executive Officer

Seminars:

Inhibiting the Dysregulated Autoinflammatory Inflammasome (NLRP3) Pathway to Treat Diabetic Retinal Diseases 2:45 pm

Developing an orally administered small molecule for the treatment of Diabetic Macular Edema and Chronic Kidney Disease with opportunity for effects on systemic diabetic diseases Highlighting the benefits of oral administration to treat autoinflammatory (NLRP3) diabetic retinal disease, is the ability to treat both eyes simultaneously in a disease which is bilateral Discussing InflammX moving…Read more

day: Day One